Participant is currently taking an enzyme inducer of CYP2C8 (carbamazepine [Carbatrol, Epitol, Equetro, Tegretol] cortisol [Hydrocortisone]; dexamethasone [Decadron]; phenobarbital [Luminal Sodium]; phenytoin [Dilantin, Phenytek, Novaplus Phenytoin Sodium]; primidone [Mysoline]; rifampin [Rifadin, Rimactane]; rifapentine [Priftin]; secobarbital [Seconal])
Patients receiving strong inhibitors of cytochrome P450 family 3, subfamily A, polypeptide 4 (CYP3A4)\r\n* Use of the following strong or moderate inhibitors are prohibited =< 7 days prior to registration\r\n** Boceprevir (Victrelis)\r\n** Clarithromycin (Biaxin, Biaxin XL)\r\n** Conivaptan (Vaprisol)\r\n** Itraconazole (Sporanox)\r\n** Ketoconazole (Nizoral)\r\n** Nefazodone (Serzone)\r\n** Posaconazole (Noxafil)\r\n** Telithromycin (Ketek)\r\n** Voriconazole (Vfend)\r\n* Use of the following inducers are prohibited =< 12 days prior to registration\r\n** Bosentan (Tracleer)\r\n** Carbamazepine (Carbatrol, Epitol, Equetro, Tegretol, Tegretol-XR)\r\n** Modafinil (Provigil)\r\n** Phenobarbital (Luminal)\r\n** Phenytoin (Dilantin, Phenytek)\r\n** Rifabutin (Mycobutin)\r\n** Rifampin (Rifadin)\r\n** St. John’s wort
Receiving any medications or substances that are inducers of CYP3A4; use of the following inducers are prohibited =< 7 days prior to registration\r\n* Strong inducers of CYP3A4/5; > 80% decrease in AUC\r\n** Avasimibe\r\n** Carbamazepine (Carbatrol, Epitol, Equetro, Tegretol, Tegretol-XR)\r\n** Phenytoin (Dilantin, Phenytek)\r\n** Rifampin (Rifadin)\r\n** St. John’s wort\r\n** Mitotane\r\n** Rifabutin\r\n** Phenobarbital\r\n* Moderate inducers of CYP3A4/5; 50-80% decrease in AUC\r\n** Bosentan (Tracleer)\r\n** Efavirenz (Sustiva)\r\n** Etravirine (Intelence)\r\n** Modafinil (Provigil)\r\n** Nafcillin\r\n** Genistein\r\n** Ritonavir\r\n** Talyiraline\r\n** Thioridazine\r\n** Tipranavir\r\n** Nevirapine (Viramune)\r\n** Phenobarbital (Luminal)\r\n** Rifabutin (Mycobutin)\r\n** Troglitazone
Receiving any medications or substances that are inducers of CYP3A4; use of the following inducers are prohibited =< 7 days prior to registration; concurrent use is not allowed simultaneously with nilotinib during the study\r\n* Strong inducers of CYP3A4/5 > 80% decrease in AUC\r\n** Avasimibe\r\n** Carbamazepine (Carbatrol, Epitol, Equetro, Tegretol, Tegretol-XR)\r\n** Phenytoin (Dilantin, Phenytek)\r\n** Rifampin (Rifadin)\r\n** St. John’s wort\r\n* Moderate inducers of CYP3A4/5 50-80% decrease in AUC\r\n** Bosentan (Tracleer)\r\n** Efavirenz (Sustiva)\r\n** Etravirine (Intelence)\r\n** Modafinil (Provigil)\r\n** Nafcillin\r\n** Nevirapine (Viramune)\r\n** Phenobarbital (Luminal)\r\n** Rifabutin (Mycobutin)\r\n** Troglitazone
Receiving any medications or substances that are strong or moderate inducers of CYP3A4; use of the following inducers are prohibited =< 7 days prior to randomization: efavirenz (Sustiva), nevirapine (Viramune), carbamazepine (Carbatrol, Epitol, Equetro, Tegretol, Tegretol-XR), modafinil (Provigil), phenobarbital (Luminal), phenytoin (Dilantin, Phenytek), pioglitazone (Actos), rifabutin (Mycobutin), rifampin (Rifadin), St. John’s wort
Taking strong inhibitors or strong/moderate inducers of cytochrome P450 (CYP)3A4\r\n* Strong inhibitors of CYP3A4/5; > 5-fold increase in the plasma area under the curve (AUC) values or more than 80% decrease in clearance\r\n** Clarithromycin (Biaxin®, Biaxin XL®)\r\n** Conivaptan (Vaprisol®)\r\n** Grapefruit juice\r\n** Itraconazole (Sporanox®)\r\n** Ketoconazole (Nizoral®)\r\n** Mibefradil\r\n** Nefazodone (Serzone®)\r\n** Posaconazole (Noxafil®)\r\n** Telaprevir (Incivek®)\r\n** Telithromycin (Ketek®)\r\n* Use of the following inducers are prohibited =< 7 days prior to registration\r\n** Strong inducers of CYP3A4/5; > 80% decrease in AUC\r\n*** Avasimibe\r\n*** Carbamazepine (Carbatrol®, Epitol®, Equetro™, Tegretol®, Tegretol-XR®)\r\n*** Phenytoin (Dilantin®, Phenytek®)\r\n*** Rifampin (Rifadin®)\r\n*** St. John’s wort\r\n** Moderate inducers of CYP3A4/5; 50-80% decrease in AUC\r\n*** Bosentan (Tracleer®)\r\n*** Modafinil (Provigil®)\r\n*** Nafcillin\r\n*** Phenobarbital (Luminal®)\r\n*** Rifabutin (Mycobutin®)\r\n*** Troglitazone
Use of the following inducers are prohibited =< 12 days prior to registration\r\n* Avasimibe\r\n* Bosentan (Tracleer®)\r\n* Carbamazepine (Carbatrol®, Epitol®, Equetro™, Tegretol®, Tegretol-XR®)\r\n* Efavirenz (Sustiva®)\r\n* Modafinil (Provigil®)\r\n* Phenobarbital (Luminal®)\r\n* Phenytoin (Dilantin®, Phenytek®)\r\n* Rifabutin (Mycobutin®)\r\n* Rifampin (Rifadin®)\r\n* St. John’s wort
Receiving any medications or substances that are inducers of CYP3A4; use of the following inducers are prohibited =< 7 days prior to registration\r\n* Inducers of CYP3A4 \r\n** Efavirenz (Sustiva)\r\n** Nevirapine (Viramune)\r\n** Carbamazepine (Carbatro, Epitol, Equetro, Tegretol, Tegretol-XR)\r\n** Modafinil (Provigil)\r\n** Phenobarbital (Luminal)\r\n** Phenytoin (Dilantin, Phenytek)\r\n** Pioglitazone (Acto)\r\n** Rifabutin (Mycobutin)\r\n** Rifampin (Rifadin)\r\n** St. John’s wort
